title: Olanzapine in the treatment of refractory nausea and vomiting: a case report and review of the literature.
abstract: The role of olanzapine in chemotherapy-induced nausea and vomiting (CINV) is supported from randomized controlled trials and national consensus guidelines such as the National Comprehensive Cancer Network. In contrast, the role of olanzapine in refractory non-CINV is limited to case reports/series, retrospective studies, one pilot study, and one randomized controlled trial in patients with major depressive disorder. We present a case of a 36-year-old man with dyskeratosis congenita and refractory non-CINV over several years in which low-dose olanzapine was effective and tolerable. We aim to contribute to the growing evidence supporting the use of olanzapine for refractory non-CINV. Furthermore, we review and summarize the literature regarding olanzapine in the CINV and non-CINV settings.
authors.forename: Michael
authors.initials: M
authors.lastname: Langley-DeGroot
authors.forename: Joseph D
authors.initials: JD
authors.lastname: Ma
authors.forename: Jeremy
authors.initials: J
authors.lastname: Hirst
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Roeland
mesh_terms: D000328:Adult; D000932:Antiemetics / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy*; D000077152:Olanzapine; D010166:Palliative Care / Q000379:methods; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
chemical_list: D000932:Antiemetics; D001569:Benzodiazepines; D000077152:Olanzapine
keywords: non–chemotherapy-induced nausea vomiting; olanzapine; refractory